Why IBM still believes that Ireland is open for business

In a recent article by Karlin Lillington in the Irish Times on 2nd April 2010, the now retired from a 36- year career with IBM, Pat Toole was still central to IBM’s decision, announced last week, to create a €66 million 200- job Dublin Smarter Cities Technology Centre that will look at how to build and manage core systems for transport, water, energy and communication.

Fifteen years ago, as a senior vice-president in the company, Toole was pivotal in the decision in 1996 to expand vastly IBM’s Irish presence from a sales organisation to a 2,000-plus manufacturing and, eventually, research campus.

When he retired, he worked on the Irish government’s Foresight committee and, five years later, was involved in the establishment of Science Foundation Ireland. He has advised IDA Ireland, Forfás and the Taoiseach.

“I’m interested in nano science and I follow [nano science research centres] Crann [at Trinity College] and Tyndall [at UCC]. And I was asked to Farmleigh.”

Read the full Irish Times article.

Queens and Seagate create eight new PhD’s in ‘nanotechnology’

Queen’s University is advertising eight new PhD positions in ‘nanotechnology’ in a partnership with technology company Seagate.

The positions in Queen’s School of Maths and Physics follow January’s announcement by Seagate of a £47.3m investment in its plant in Springtown, Londonderry, backed up by £12.7m from Invest Northern Ireland.

Researchers in the university’s centre for nanostructured media will set up a new facility with a laboratory of large area depositions systems, magnetometers, focused ion beam and atom probe microscopes.

Abbott to use Elan’s NanoCrystal® Technology

Elan announced that it has entered into a License Agreement with Abbott Pharmaceutical in which Abbott has been granted US rights, in a partnership with AstraZeneca Pharmaceuticals, LP, to utilize Elan’s proprietary NanoCrystal Technology to develop and commercialize a single fixed-dose combination product containing the active pharmaceutical ingredients in Abbott’s TriCor® and AstraZeneca’s Crestor® products.

The drug in nano-form can be incorporated into common dosage forms, including tablets, capsules, inhalation devices, and sterile forms for injection, with the potential for substantial improvements to clinical performance.

For more information Click Here.